Keytamine

Nabokov · 2025 · $7.99 · Action · deal grade D

• Estimated net residual revenue: $125 to $188 per month
• Opportunity: $156 per month at x1.00 dormancy
• Estimated lifetime owners: 1.2k
• 84%% positive across 45 reviews · 2.3 reviews/month

Why it's flagged

• Developer active, last post 7 months ago
• Last build shipped 7 months ago
• Last discounted 0 months ago, 7 sales in the last 12 months

This case as Markdown · Estimates carry ±30-50%% error per title.